Stocks and Investing
Stocks and Investing
Thu, August 15, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, August 14, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Upgraded (CDTX) to Strong Buy and Held Target at $24 on, Aug 14th, 2024
Ed Arce of HC Wainwright & Co., Upgraded "Cidara Therapeutics, Inc." (CDTX) to Strong Buy and Held Target at $24 on, Aug 14th, 2024.
Ed has made no other calls on CDTX in the last 4 months.
There is 1 other peer that has a rating on CDTX. Out of the 1 peers that are also analyzing CDTX, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Stephen Brozak of "WBB Securities" Maintained at Strong Buy and Held Target at $40 on, Thursday, April 25th, 2024
Contributing Sources